These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30155861)

  • 1. Two-year longitudinal evaluation of a second-generation thin-strut sirolimus-eluting bioresorbable coronary scaffold with hybrid cell design in porcine coronary arteries.
    Gasior P; Cheng Y; Xia J; Conditt GB; McGregor JC; Virmani R; Granada JF; Kaluza GL
    Cardiol J; 2020; 27(2):115-125. PubMed ID: 30155861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Characterization of Biomechanical Behavior and Healing Profile of a Novel Ultra-High-Molecular-Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
    Cheng Y; Gasior P; Shibuya M; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2016 Oct; 9(10):. PubMed ID: 27694138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Biomechanical Behavior and Healing Profile of a Novel Thinned Wall Ultrahigh Molecular Weight Amorphous Poly-l-Lactic Acid Sirolimus-Eluting Bioresorbable Coronary Scaffold.
    Cheng Y; Gasior P; Xia JG; Ramzipoor K; Lee C; Estrada EA; Dokko D; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
    Circ Cardiovasc Interv; 2017 Jul; 10(7):. PubMed ID: 28701488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
    Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
    JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in haemodynamic microenvironment in vessels scaffolded with Absorb BVS and Mirage BRMS: insights from a preclinical endothelial shear stress study.
    Tenekecioglu E; Torii R; Bourantas C; Sotomi Y; Cavalcante R; Zeng Y; Collet C; Crake T; Suwannasom P; Onuma Y; Serruys PW
    EuroIntervention; 2017 Dec; 13(11):1327-1335. PubMed ID: 28590249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: the potential implications for clinical practice.
    Farooq V; Serruys PW; Heo JH; Gogas BD; Onuma Y; Perkins LE; Diletti R; Radu MD; Räber L; Bourantas CV; Zhang Y; van Remortel E; Pawar R; Rapoza RJ; Powers JC; van Beusekom HM; Garcìa-Garcìa HM; Virmani R
    JACC Cardiovasc Interv; 2013 May; 6(5):523-32. PubMed ID: 23702016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent: 180 days follow-up in a porcine model.
    Shen L; Wu Y; Ge L; Zhang Y; Wang Q; Qian J; Qiu Z; Ge J
    Int J Cardiovasc Imaging; 2017 Oct; 33(10):1473-1481. PubMed ID: 28639098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-year clinical and two-year multimodality imaging outcomes of a thin-strut sirolimus-eluting bioresorbable vascular scaffold: MeRes-1 trial.
    Seth A; Onuma Y; Chandra P; Bahl VK; Manjunath CN; Mahajan AU; Kumar V; Goel PK; Wander GS; Kaul U; Ajit Kumar VK; Abizaid A; Serruys PW
    EuroIntervention; 2019 Sep; 15(7):607-614. PubMed ID: 31147308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Evaluation of a Novel Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold in Porcine Coronary Artery at 6 Months.
    Zheng JF; Qiu H; Tian Y; Hu XY; Luo T; Wu C; Tian Y; Tang Y; Song LF; Li L; Xu L; Xu B; Gao RL
    JACC Cardiovasc Interv; 2019 Feb; 12(3):245-255. PubMed ID: 30732729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Head-to-head comparison of the neointimal response between metallic and bioresorbable everolimus-eluting scaffolds using optical coherence tomography.
    Gomez-Lara J; Brugaletta S; Farooq V; Onuma Y; Diletti R; Windecker S; Thuesen L; McClean D; Koolen J; Whitbourn R; Dudek D; Smits PC; Chevalier B; Regar E; Veldhof S; Rapoza R; Ormiston JA; Garcia-Garcia HM; Serruys PW
    JACC Cardiovasc Interv; 2011 Dec; 4(12):1271-80. PubMed ID: 22192368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic analysis of a novel bioresorbable scaffold in porcine coronary artery model.
    Tenekecioglu E; Torii R; Bourantas CV; Cavalcante R; Sotomi Y; Zeng Y; Collet C; Crake T; Abizaid A; Onuma Y; Su S; Santoso T; Serruys PW
    Catheter Cardiovasc Interv; 2018 May; 91(6):1084-1091. PubMed ID: 28843033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation with in vivo optical coherence tomography and histology of the vascular effects of the everolimus-eluting bioresorbable vascular scaffold at two years following implantation in a healthy porcine coronary artery model: implications of pilot results for future pre-clinical studies.
    Gogas BD; Radu M; Onuma Y; Perkins L; Powers JC; Gomez-Lara J; Farooq V; Garcia-Garcia HM; Diletti R; Rapoza R; Virmani R; Serruys PW
    Int J Cardiovasc Imaging; 2012 Mar; 28(3):499-511. PubMed ID: 21503708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro mechanical behavior and in vivo healing response of a novel thin-strut ultrahigh molecular weight poly-l-lactic acid sirolimus-eluting bioresorbable coronary scaffold in normal swine.
    Cheng Y; Gasior P; Ramzipoor K; Lee C; McGregor JC; Conditt GB; McAndrew T; Kaluza GL; Granada JF
    Int J Cardiol; 2019 Jul; 286():21-28. PubMed ID: 30967275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Post-implantation shear stress assessment: an emerging tool for differentiation of bioresorbable scaffolds.
    Tenekecioglu E; Torii R; Katagiri Y; Chichareon P; Asano T; Miyazaki Y; Takahashi K; Modolo R; Al-Lamee R; Al-Lamee K; Colet C; Reiber JHC; Pekkan K; van Geuns R; Bourantas CV; Onuma Y; Serruys PW
    Int J Cardiovasc Imaging; 2019 Mar; 35(3):409-418. PubMed ID: 30426299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neointimal coverage and late apposition of everolimus-eluting bioresorbable scaffolds implanted in the acute phase of myocardial infarction: OCT data from the PRAGUE-19 study.
    Toušek P; Kočka V; Malý M; Lisa L; Buděšínský T; Widimský P
    Heart Vessels; 2016 Jun; 31(6):841-5. PubMed ID: 25896128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
    Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
    JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.